Tocilizumab – VJRegenMed

CAR T-cells in adult ALL

Marta Palhas — Fri, 26 Feb 2021 14:08:28 +0000

CD19-directed CAR T-cells have been approved for use in children and young adults up to the age of 25 years with acute lymphoblastic leukemia (ALL). Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines the use of CAR T-cells in adult ALL. Several prognostic factors for CAR-T therapy’s success have been identified, including platelet count before CAR-T infusion, lactate dehydrogenase (LDH) level, and mutated p53. Additionally, Prof. Nagler discusses if CAR T-cells are the definitive therapy for ALL or a pathway to allogeneic transplant. Finally, Prof. Nagler shares new approaches for CAR T-cells in ALL, including CD22-directed CAR T-cells, sequential administration of CD19 and CD22 CAR T-cells, bispecific CARs, and allogeneic CAR T-cells. This interview took place during the 3rd European CAR T-cell Meeting.

ARI-0001 CART19 cells in R/R B-ALL with isolated extramedullary disease

admin_vjr_user — Fri, 26 Feb 2021 14:08:22 +0000

Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the safety and efficacy outcomes of ARI-0001 CART19 cell therapy in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with isolated extramedullary disease. Results show a good safety profile, the incidence of cytokine-release syndrome (CRS) was 40%, and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. Additionally, ARI-0001 therapy was able to achieve long-term remissions in this population of patients. This interview took place during the 3rd European CAR T-cell Meeting.

CAR T-cell toxicity: CRS, ICANS and prolonged cytopenias

Marta Palhas — Fri, 26 Feb 2021 14:08:22 +0000

Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, discusses recognition and treatment of CAR T-cell therapy-related side effects, including novel insights into the pathophysiology of long-term cytopenias. Close monitoring and timely intervention with tocilizumab with or without corticosteroids remain the best management strategies for cytokine release syndrome (CRS). The pathogenesis of neurotoxicity is not fully understood and it remains very challenging to manage. Similar to CRS management, neurotoxicity needs to be promptly recognized. Additionally, Prof. Subklewe shares the latest updates regarding prolonged cytopenias. This interview took place during the 3rd European CAR T-cell Meeting.

Tocilizumab: CAR T-cell therapy in DLBCL

admin_vjr_user — Thu, 08 Oct 2020 14:08:11 +0000

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR T-cell therapy for treatment of cytokine release syndrome (CRS) in refractory diffuse large B-cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).